Abstract:2039 Background: The human cytomegalovirus (CMV) antigen pp65 is ubiquitously expressed in high-grade glioma (HGG) and medulloblastoma but not in adjacent brain. The primary objective of this first-in-human phase I trial (NCT03299309) was to assess the safety and feasibility of a novel peptide vaccine targeting pp65 (PEP-CMV) in children/young adults with recurrent medulloblastoma and HGG. Methods: The vaccine is comprised of a synthetic long peptide of 26 amino acids and is administered as an emulsion in Montanide ISA 51. Patients receive a single 5-day course of temozolomide to induce lymphopenia, tetanus/diphtheria toxoid site preconditioning to promote dendritic cell migration, then PEP-CMV administered intradermally in the groin every two weeks for 3 doses, then monthly. Results: Forty-two patients were enrolled. Diagnoses include medulloblastoma (n=2), glioblastoma (n=21), anaplastic oligodendroglioma (n=3), anaplastic astrocytoma (n=11), and malignant glioma NOS (n=5). The median time from initial diagnosis to treatment was 24 months (range 4-35) and the median number of prior chemotherapy regimens was 4 (range 0-15). The mean age was 23.2 ± 9.3 years. 55% of patients were male. The median KPS was 80. Of the 38 patients who received PEP-CMV, the maximum grade adverse event (AE) possibly, probably, or definitely related to PEP-CMV was as follows: 17 (45%) had Grade 1 adverse events (AE), 16 (42%) had Grade 2 AEs, 2 (5%) had Grade 3 AEs (encephalopathy and pyramidal tract syndrome), and one (3%) had a Grade 4 AE (cerebral edema). One patient developed symptoms and had elevated inflammatory cytokines consistent with cytokine release syndrome (Grade 2). The median progression-free survival was 2.5 months (95% CI:2.2,3.2) and median overall survival was 6.4 months (95% CI:3.4,7.9). The 12-month OS was 26.6% (95% CI:14,41.1%). Of the 22 patients with evaluable immune monitoring data, T cell reactivity on IFNγ pp65 ELISpot was increased after PEP-CMV delivery (median spot pretreatment vs. prior to vaccine #4: 1 vs 30, P=0.004, Table). Lower percentage of pretreatment regulatory T cells and higher percentage of terminally differentiated effector T cells at vaccine #4 were associated with longer subsequent survival. Conclusions: PEP-CMV is well-tolerated and elicits an antigen-specific immune response in heavily pretreated, multiply recurrent patients with a 12-month OS of 26.6%. A multi-institutional Phase II trial (NCT05096481) of PEP-CMV is opening imminently. Clinical trial information: NCT03299309 . [Table: see text]

Phase 1 dose-finding study to evaluate safety and tolerability of CVGBM in patients with newly diagnosed and surgically resected MGMT-unmethylated glioblastoma.

P06.09.B TRIAL IN PROGRESS: PHASE 1 DOSE-FINDING STUDY TO EVALUATE SAFETY AND TOLERABILITY OF CVGBM IN PATIENTS WITH NEWLY DIAGNOSED AND SURGICALLY RESECTED MGMT-UNMETHYLATED GLIOBLASTOMA

Ctim-08. First In Human Study Of The Mrna-Based Cancer Vaccine Cvgbm In Patients (Pts) With Newly-Diagnosed And Surgically Resected Mgmt-Unmethylated Glioblastoma (Gbm): First Results From The Dose Escalation Phase

Evaluation of tumor responses and overall survival in patients with recurrent glioblastoma (GBM) from a phase IIa trial of a CMV vaccine immunotherapeutic candidate (VBI-1901).

Ctim-25. Phase2B/3 Study Of Neoantigen-Specific T Cell Immunotherapy In Newly Diagnosed O6 – Methylguanine Methyltransferase Unmethylated (Mgmt -) Glioblastoma

Ctim-10. Phase 1 Trial Of Personalized Neoantigen Vaccines In Combination With Standard Care To Treat Glioblastoma

Phase I trial of adjuvant mature autologous dendritic cell/allogeneic tumor lysate vaccines in combination with temozolomide in newly diagnosed glioblastoma

Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment

ACTR-71. PHASE 1/2 STUDY OF DIANHYDROGALACTITOL (VAL-083) WITH RADIATION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED, MGMT-UNMETHYLATED GLIOBLASTOMA

Ctim-29. Tumor Responses In A Randomized Phase Iib Trial Of A Cmv Vaccine Immunotherapeutic Candidate (Vbi-1901) In Recurrent Glioblastomas

CTIM-07. PHASE IIB RANDOMIZED, BLINDED, CONTROLLED TRIAL EVALUATING NEOADJUVANT PD-1 BLOCKADE COMBINED WITH A2B5+ GLIOMA STEM-LIKE CELL LYSATE-LOADED DCV IN RECURRENT GLIOBLASTOMA (IDH1/2 -)- TRAIL IN PROGRESS

Integrating multisector molecular characterization into personalized peptide vaccine design for patients with newly diagnosed glioblastoma

48 Phase 2 studies of dianhydrogalactitol (VAL-083) in patients with glioblastoma, MGMT-unmethylated

Ctim-12. A Retrolective Analysis On The Safety, Efficacy And Immunogenicity Of 203 Glioblastoma Patients Treated With Personalized Therapeutic Cancer Vaccines (Ptcv)

Results from the first step of a phase II study of vaccination with autologous dendritic cells loaded with autologous tumour homogenate in glioblastoma.

Outcomes and immune response after peptide vaccination targeting human cytomegalovirus antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma.

CTIM-14. COMPREHENSIVE BIOMARKER ANALYSIS OF RESPONDERS AND NON-RESPONDERS IN A PHASE IIA TRIAL OF A CMV VACCINE IMMUNOTHERAPEUTIC CANDIDATE (VBI-1901)

Actively personalized vaccination trial for newly diagnosed glioblastoma

INB-200 phase I study of gene modified autologous gamma-delta (γδ) T cells in patients with newly diagnosed glioblastoma multiforme (GBM) receiving maintenance temozolomide (TMZ).

First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity

A multicenter, randomized, placebo-controlled phase IIb trial of an autologous formalin-fixed tumor vaccine for newly diagnosed glioblastomas